1 / 11

RISPOSTA AL VACCINO ANTI-EPATITE B IN CONSUMER ANTI-HCV POSITIVI.

RISPOSTA AL VACCINO ANTI-EPATITE B IN CONSUMER ANTI-HCV POSITIVI. A.Apicella ,*P.Oliva,*N.Caso,***R.Punzi,***N.Boffa, **L.Stella,***M. Mazzeo .

zipporah
Download Presentation

RISPOSTA AL VACCINO ANTI-EPATITE B IN CONSUMER ANTI-HCV POSITIVI.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RISPOSTA AL VACCINO ANTI-EPATITE B IN CONSUMER ANTI-HCV POSITIVI. A.Apicella,*P.Oliva,*N.Caso,***R.Punzi,***N.Boffa, **L.Stella,***M. Mazzeo. Ser.T. di Salerno ASL SA/2; * Ser.T. Mercato S. Severino ASL SA/2; ** Ser.T. Somma Vesuviana ASL NA/4; *** Azienda Ospedaliera di Rilievo Nazionale “OO.RR.San Giovanni di Dio e Ruggi d’Aragona” di Salerno

  2. Chlabicz S., Lapinski T. W., Grzeszczuk A., Prokopowicz D. Four-year follow up of hepatitis C patients vaccinated against hepatitis B virus. World J Gastroenterol 2005;11(12):1798-1801.

  3. Leroy V., Bourliere M. et al. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus load in patients with chronic hepatitis C: a case-control study. Eur J Gastroenterol Hepatol 2002;14:485-489.

  4. In Italia la popolazione dei consumer (CSR) risulta HCV positiva dal 48% all’85%, con un gradiente Nord-Sud a maggiore prevalenza nelle regioni meridionali.

  5. OBIETTIVO Valutazione della risposta al vaccino anti-epatite B in consumer anti-HCV positivi.

  6. MATERIALI E METODI Vaccino ricombinante anti-epatite B Dose: 10 µg Schedula standard: 0, 1, 6 mesi 103 pazienti (52 pz HCV+ ; 51 pz HCV-) Età 28-40 anni (34 ± 6) Sesso: M 88, F 15

  7. PAZIENTI VACCINATI

  8. RISPOSTA VACCINO IN PZ. HCV - 51 30 (59%) 21 (41%)

  9. RISPOSTA VACCINO IN PZ. HCV + 52 37 (71%) 15 (29%)

  10. RISULTATI La risposta al vaccino in CSR anti-HCV + era significativamente più bassa rispetto ai pazienti anti-HCV – : • 15 responders (29%) / 52 pz anti-HCV + • 30 responders (59%) / 51 pz anti-HCV –

  11. CONCLUSIONI • La risposta al vaccino anti-epatite B nei CSR HCV + appare ridotta. • Questi risultati sono in contrasto con studi precedenti condotti su CSR nei quali non veniva evidenziata una diminuzione di responders in pazienti anti-HCV +. (Minniti et al.,Vaccine 1999) (Borg et al., Addiction 1999)

More Related